IN8bio presents ‘positive’ data from iPSC platform at SITC

IN8bio presented new positive preclinical data from its induced pluripotent stem cell gamma-delta T cell platform at the Society for Immunotherapy of Cancer’s 38th Annual Meeting. The data represents a significant advance in the development of the INB-500 iPSC program towards the development of allogeneic gamma-delta T cell therapies. “Our deep understanding of gamma-delta T cell biology allows for significant ex vivo expansion capabilities,” said William Ho, Co-founder and CEO. “We have successfully developed and utilized a robust serum and feeder-free process for generating iPSC derived gamma-delta T cells, representing an important step towards developing a truly allogeneic ‘off-the-shelf’ gamma-delta T cell source for therapeutic development.” The presented data underscores the platform’s ability to reprogram donor cells into iPSCs, expand them, and guide their differentiation into gamma-delta T cells through IN8bio’s proprietary process, which can be scaled for full GMP manufacturing. Notably, the platform enables the differentiation into both Vd1+ and Vd2+ cell subtypes using cell-type specific processes. The iPSC-derived gamma-delta T cells underwent comprehensive characterization, encompassing morphological analysis, cell surface markers and functional assessment via tumor cell killing assays.